Patents by Inventor Francesco Piscitelli
Francesco Piscitelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150332Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: ApplicationFiled: September 19, 2023Publication date: May 9, 2024Inventors: Paolo PEVARELLO, William J. RAY, Mary HAMBY, Yaima Luzardo LIGHTFOOT, Philip JONES, Russell THOMAS, Chiara LIBERATI, Domenica TORINO, Valentina CUSANO, Francesco PISCITELLI, Ali Munaim YOUSIF, Silvia BOVOLENTA
-
Patent number: 11958839Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: GrantFiled: September 22, 2021Date of Patent: April 16, 2024Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, GOLGI NEUROSCIENCES, S.R.L.Inventors: Paolo Pevarello, William J. Ray, Mary Hamby, Yaima Luzardo Lightfoot, Philip Jones, Russell Thomas, Chiara Liberati, Domenica Torino, Valentina Cusano, Francesco Piscitelli, Ali Munaim Yousif, Silvia Bovolenta
-
Publication number: 20240034737Abstract: The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.Type: ApplicationFiled: December 16, 2021Publication date: February 1, 2024Applicant: BREYE THERAPEUTICS APSInventors: Paolo PEVARELLO, Mariangela SODANO, Valentina CUSANO, Francesco PISCITELLI, Domenica TORINO, Rocco VITALONE, Ali Munaim YOUSIF, Oleksii ARTAMONOV
-
Publication number: 20230386514Abstract: According to an embodiment, a circuit includes a biasing and a low-frequency recovery circuit. The biasing circuit includes a voltage digital to analog converter (V-DAC), a differential difference amplifier coupled to the V-DAC, a common-mode feedback (CMFB) amplifier coupled to the differential difference amplifier, and a first pair of transistors arranged as a high-impedance structure and coupled to the differential difference amplifier and the CMFB amplifier. The low-frequency recovery circuit includes a current digital to analog converter (C-DAC), a second pair of transistors arranged as a high-impedance structure and coupled to the first pair of transistors, a pair of resistors having a resistance value equal to half a resistance of the resistive sensor, the pair of resistors arranged between the second pair of transistors and coupled to the C-DAC, and a gain circuit coupled to shared nodes between the second pair of transistors and the pair of resistors.Type: ApplicationFiled: March 28, 2023Publication date: November 30, 2023Inventors: Dario Livornesi, Alessio Emanuele Vergani, Paolo Pulici, Francesco Piscitelli, Enrico Mammei, Mojtaba Mohammadi Abdevand, Piero Malcovati, Edoardo Bonizzoni
-
Publication number: 20230314117Abstract: According to an embodiment, a circuit includes a core and low-frequency recovery circuits. The core circuit is configured to bias a resistive sensor used to measure a fly height of a hard disk drive. The core circuit is additionally configured to amplify a high-frequency component of a sensing signal of the resistive sensor, the sensing signal indicating the fly height. The low-frequency recovery circuit is configured to amplify the sensing signal's low-frequency component.Type: ApplicationFiled: March 28, 2023Publication date: October 5, 2023Inventors: Dario Livornesi, Mattia Fausto Moretti, Paolo Pulici, Alessio Emanuele Vergani, Alessio Facen, Michele Bartolini, Roberto Faravelli, Francesco Piscitelli
-
Patent number: 11597702Abstract: Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.Type: GrantFiled: March 12, 2019Date of Patent: March 7, 2023Assignee: GOLGI NEUROSCIENCES S.R.L.Inventors: Domenica Torino, Francesco Piscitelli, Valentina Cusano, Rocco Vitalone, Andrew Griffin, Russell Thomas, Paolo Pevarello, Ali Munaim Yousif
-
Publication number: 20230010299Abstract: Disclosed is a compound of formula (I) or a stereoisomer thereof, or a salt of any of the foregoing and to processes for its preparation. The compounds of formula (I) are useful in the treatment TRPML1-mediated disorders or diseases.Type: ApplicationFiled: November 12, 2020Publication date: January 12, 2023Inventors: Paolo PEVARELLO, Valentina CUSANO, Mariangela SODANO, Domenica TORINO, Rocco VITALONE, Chiara LIBERATI, Francesco PISCITELLI
-
Publication number: 20220259191Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: ApplicationFiled: September 22, 2021Publication date: August 18, 2022Inventors: Paolo PEVARELLO, William J. RAY, Mary HAMBY, Yaima Luzardo LIGHTFOOT, Philip JONES, Russell THOMAS, Chiara LIBERATI, Domenica TORINO, Valentina CUSANO, Francesco PISCITELLI, Ali Munaim YOUSIF, Silvia BOVOLENTA
-
Patent number: 11155538Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: GrantFiled: July 23, 2020Date of Patent: October 26, 2021Assignees: Board of Regents, The University of Texas System, Axxam S.p.A.Inventors: Paolo Pevarello, William J. Ray, Mary Hamby, Yaima Luzardo Lightfoot, Philip Jones, Russell Thomas, Chiara Liberati, Domenica Torino, Valentina Cusano, Francesco Piscitelli, Ali Munaim Yousif, Silvia Bovolenta
-
Publication number: 20210087148Abstract: Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.Type: ApplicationFiled: March 12, 2019Publication date: March 25, 2021Inventors: Domenica TORINO, Francesco PISCITELLI, Valentina CUSANO, Rocco VITALONE, Andrew GRIFFIN, Russell THOMAS, Paolo PEVARELLO, Ali Munaim YOUSIF
-
Publication number: 20210024510Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: ApplicationFiled: July 23, 2020Publication date: January 28, 2021Inventors: Paolo PEVARELLO, William J. RAY, Mary HAMBY, Yaima Luzardo LIGHTFOOT, Philip JONES, Russell THOMAS, Chiara LIBERATI, Domenica TORINO, Valentina CUSANO, Francesco PISCITELLI, Ali Munaim YOUSIF, Silvia BOVOLENTA
-
Patent number: 8927586Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.Type: GrantFiled: February 28, 2013Date of Patent: January 6, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
-
Patent number: 8530520Abstract: The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.Type: GrantFiled: June 6, 2012Date of Patent: September 10, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Onur Atasoylu, Carlo Ballatore, Kurt R. Brunden, Longchuan Huang, Donna M. Huryn, Michael James, Virginia M. Y. Lee, Francesco Piscitelli, Amos B. Smith, III, James Soper, John Q. Trojanowski
-
Publication number: 20130190370Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.Type: ApplicationFiled: July 27, 2011Publication date: July 25, 2013Applicant: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
-
Publication number: 20130029983Abstract: The present invention is directed to methods of inhibiting a tauopathy in a patient by administration of a compound of formula I: Novel aminothienopyridazine compounds are also described.Type: ApplicationFiled: September 22, 2010Publication date: January 31, 2013Inventors: Carlo Ballatore, Kurt R. Brunden, Alexander L. Crowe, Donna M. Huryn, Virginia M.Y. Lee, John Q. Trojanowski, Amos B. Smith, III, Ruili Huang, Wenwei Huang, Ronald L. Johnson, Francesco Piscitelli
-
Publication number: 20120329877Abstract: The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R1 is H or C1-6alkyl and R2 is H, C1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and X is O or N; as well as tautomers and pharmaceutically acceptable salt forms thereof. Uses of these compounds are also described.Type: ApplicationFiled: June 6, 2012Publication date: December 27, 2012Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Onur Atasoylu, Carlo Ballatore, Kurt R. Brunden, Longchun Huang, Donna M. Huryn, Michael James, Virginia M.Y. Lee, Francesco Piscitelli, Amos B. Smith, III, James Soper, John Q. Trojanowski